Project: Lactomezole, a safe and effective eradication therapy for H. Pylori without the use of antibiotics

Acronym AVVALACT (Reference Number: 11089)
Duration 04/09/2017 - 04/09/2020
Project Topic To develop a product, Lactomezole, as a new innovative standard of care for the management of dyspepsia and first line treatment for H. pylori infection, which is associated with dyspeptic and gastro-intestinal conditions, including gastric cancer. Lactomezole has significant OTC potential, as it will be the first proton pump inhibitor (PPI) plus prebiotic combo that has demonstrated eradication of H. pylori and normalization of GI tract microbiota without the use of antibiotics.
Network Eurostars 2
Call Eurostars Cut-Off 6

Project partner

Number Name Role Country
1 AVVA Pharmaceuticals Ltd Coordinator Cyprus
2 ProtATonce Ltd Partner Greece
3 Cyprus University of Technology Partner Cyprus